Published online before print June 4, 2009, doi: 10.1161/STROKEAHA.108.543561
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2009;40:2433.)
© 2009 American Heart Association, Inc.
Original Contributions |
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window
Joint Outcome Table Analysis of the ECASS 3 Trial
From Stroke Center (J.L.S., D.L., S.S.) and Departments of Neurology (J.L.S., D.L., S.S.), Biomathematics (J.G.), and Emergency Medicine (S.S.), David Geffen School of Medicine at the University of California, Los Angeles, Calif; Department of Neurology (J.Grotta), University of Texas-Houston Medical School, Houston, Tex; Oregon Stroke Center (H.L.), Oregon Health and Science University, Portland, Ore; Division of Neurology (L.S.), Massachusetts General Hospital, Boston, Mass; Department of Emergency Medicine (P.S.), University of Michigan, Ann Arbor, Mich.
Correspondence to Jeffrey L. Saver, MD, UCLA Stroke Center, 710 Westwood Plaza, Los Angeles, CA 90095. E-mail jsaver{at}ucla.edu
Background and Purpose— Measures of a therapy’s effect size are important guides to clinicians, patients, and policy-makers on treatment decisions in clinical practice. The ECASS 3 trial demonstrated a statistically significant benefit of intravenous tissue plasminogen activator for acute cerebral ischemia in the 3- to 4.5-hour window, but an effect size estimate incorporating benefit and harm across all levels of poststroke disability has not previously been derived.
Methods— Joint outcome table specification was used to derive number needed to treat to benefit (NNTB) and number needed to treat to harm (NNTH) values summarizing treatment impact over the entire outcome range on the modified Rankin scale of global disability, including both expert-dependent and expert-independent (algorithmic and repeated random sampling) array generation.
Results— For the full 7-category modified Rankin scale, algorithmic analysis demonstrated that the NNTB for 1 additional patient to have a better outcome by 
1 grades than with placebo must lie between 4.0 and 13.0. In bootstrap simulations, the mean NNTB was 7.1. Expert joint outcome table analyses indicated that the NNTB for improved final outcome was 6.1 (95% CI, 5.6–6.7) and the NNTH 37.5 (95% CI, 34.6–40.5). Benefit per 100 patients treated was 16.3 and harm per 100 was 2.7. The likelihood of help to harm ratio was 6.0.
Conclusions— Treatment with tissue plasminogen activator in the 3- to 4.5-hour window confers benefit on approximately half as many patients as treatment <3 hours, with no increase in the conferral of harm. Approximately 1 in 6 patients has a better and 1 in 35 has a worse outcome as a result of therapy.
Key Words: cerebral infarction • clinical trial • fibrinolysis • ischemic stroke • thrombolysis
Related Article:
Stroke 2009 40: 2295-2296.
This article has been cited by other articles:
 |
|
 |
|
  T. Kurth and C. Tzourio Treating Patients With Ischemic Stroke With Tissue Plasminogen Activator in the 3.5- to 4-Hour Window: Numbers Support Benefit but the Message Is to Still Go Fast Stroke, July 1, 2009; 40(7): 2295 - 2296. [Full Text] [PDF]
|
|